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2013, accepted Mabstructive sleep apnea (OSA) is an underdiagnosed condition characterized by recurrent episodes of obstruction of
the upper airway leading to sleep fragmentation and intermittent hypoxia during sleep. Obesity predisposes to OSA,
and the prevalence of OSA is increasing worldwide because of the ongoing epidemic of obesity. Recent evidence has
shown that surrogate markers of cardiovascular risk, including sympathetic activation, systemic inﬂammation, and
endothelial dysfunction, are signiﬁcantly increased in obese patients with OSA versus those without OSA, suggesting
that OSA is not simply an epiphenomenon of obesity. Moreover, ﬁndings from animal models and patients with OSA
show that intermittent hypoxia exacerbates the metabolic dysfunction of obesity, augmenting insulin resistance and
nonalcoholic fatty liver disease. In patients with the metabolic syndrome, the prevalence of moderate to severe OSA
is very high (w60%). In this population, OSA is independently associated with increased glucose and triglyceride
levels as well as markers of inﬂammation, arterial stiffness, and atherosclerosis. A recent randomized, controlled,
crossover study showed that effective treatment of OSA with continuous positive airway pressure for 3 months
signiﬁcantly reduced several components of the metabolic syndrome, including blood pressure, triglyceride levels,
and visceral fat. Finally, several cohort studies have consistently shown that OSA is associated with increased
cardiovascular mortality, independent of obesity. Taken together, these results support the concept that OSA
exacerbates the cardiometabolic risk attributed to obesity and the metabolic syndrome. Recognition and treatment
of OSA may decrease the cardiovascular risk in obese patients. (J Am Coll Cardiol 2013;62:569–76) ª 2013 by
the American College of Cardiology FoundationObstructive sleep apnea (OSA) is a clinical condition char-
acterized by recurrent episodes of complete obstruction
(apnea) or partial obstruction (hypopnea) of the upper
airway, leading to increased negative intrathoracic pressure,
sleep fragmentation, and intermittent hypoxia during sleep
(1). Research on the current prevalence of OSA indicated
that one-third of sleep studies showed some degree of OSA
(apnea-hypopnea index 5 events per hour of sleep) (2).
Among adults 30 to 70 years of age, approximately 13% of
men and 6% of women have moderate to severe forms of
OSA (apnea-hypopnea index 15 events per hour of sleep)
(2). Comparing data from 2 decades ago (3), the current
estimates represent an increase of millions of additional
afﬂicted persons and are mainly explained by the ongoing
obesity epidemic. Overall, it is estimated that 50% to 60%
of people who are obese and patients with the metabolicInstitute (InCor), University of Sáo Paulo Medical School,
yDisciplina de Medicina e Biologia do Sono, Departamento de
ersidade Federal de Sáo Paulo, Sáo Paulo, Brazil; and the zDivision
Critical Care Medicine, Department of Medicine, Johns Hopkins
of Medicine, Baltimore, Maryland. The authors have reported that
onships relevant to the content of this paper to disclose.
ived December 31, 2012; revised manuscript received May 22,
y 24, 2013.syndrome have OSA (4,5). The prevalence of OSA is even
higher in obese patients with diabetes mellitus (6) and
morbid obesity (7). Despite such an overwhelming associa-
tion, OSA remains unrecognized in the vast majority of
these patients with high pre-test probability of OSA (8).
Why is OSA so common in patients with obesity and the
metabolic syndrome? Several anatomic and functional factors
predispose to OSA. Patients with OSA are able to com-
pensate for the upper airway narrowing by increasing the
activity of upper airway muscles that maintain airway patency
during wakefulness (9). In contrast, this protective effect is
lost during sleep, when relaxation of the muscles occurs and
obstruction of the upper airways prevails. Obesity is a major
risk factor for OSA because it promotes enlargement of soft
tissue structures within and surrounding the airway, thereby
contributing signiﬁcantly to pharyngeal airway narrowing
(10,11). An excess of fat deposition has also been observed
under the mandible and in the tongue, soft palate, and uvula
(9,12). Beyond the direct effects on the upper airway, obesity
also contributes indirectly to upper airway narrowing during
sleep. Lung volumes aremarkedly reduced by a combination of
increased abdominal fat mass and recumbent posture.
Reduction of lung volume may decrease longitudinal tra-
cheal traction forces and pharyngeal wall tension, which
Figure 1 Obesity Predispo
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570predisposes to narrowing of the
airway (Fig. 1) (13). In addition,
obesity-related leptin resistance
may impair the neuroanatomic
interactions necessary for stable
breathing, thereby contributing to
the genesis of OSA (14).
The concept that OSA may be
part of the metabolic syndrome is
not new. In 1998, Wilcox et al.
proposed the name “syndrome
Z” for the combination of the
metabolic syndrome (syndrome
X) and OSA to reﬂect the closeassociation of components of the metabolic syndrome with
OSA (15). Since then, a major challenge to the ﬁeld has
been to understand whether OSA is a mere epiphenomenon
or an additional burden that exacerbates the cardiometabolic
risk of obesity and the metabolic syndrome. In the present
review, we discuss recent evidence supporting the indepen-
dent role of OSA in these scenarios. Because of space
limitations, the cardiometabolic risk of obesity and the
metabolic syndrome per se are not discussed in this review.Can OSA Have Independent Effects
on the Cardiometabolic Risk Attributed
to Obesity and the Metabolic Syndrome?
Clinical and epidemiological studies have reported an
independent association between OSA and cardiovascular
events, suggesting that OSA may lead to cardiometabolic
dysregulation (16–18). Studies in mice showed that a short-
term regimen of intermittent hypoxia (a hallmark of OSA)
caused large-amplitude oxygen swings in the liver, mirroring
swings of SpO2, whereas ﬂuctuations of oxygen levels were
attenuated in muscle and nearly abolished in adipose tissueses to Obstructive Sleep Apnea
ese patients to obstructive sleep apnea.in both lean and obese mice (19). The data in the animal
model suggest that OSA exacerbates hypoxia at the tissue
level (19). The ampliﬁcation of hypoxia in the adipose tissue
may represent an important mechanism of cardiometabolic
dysfunction in OSA because it is a major trigger of lipolysis,
chronic inﬂammation, macrophage inﬁltration, reduction of
adiponectin level, elevation of leptin level, adipocyte death,
endoplasmic reticulum stress, and mitochondrial dysfunc-
tion (20). Despite clinical and experimental evidence, the
vast majority of clinical studies that evaluated the impact of
obesity and the metabolic syndrome on cardiovascular
burden failed to consider OSA a potential confounding
factor. Reﬂecting this gap, the American Heart Association
Scientiﬁc Statement on metabolic syndrome referred to
OSA in the section of “other ﬁelds of medicine,” with the
same attention given to cholesterol gallstones and lip-
odystrophies (21). This may reﬂect a low awareness of OSA
in the cardiovascular ﬁeld associated with the perception that
OSA is merely an epiphenomenon of obesity. For didactic
purposes, we present the evidence linking OSA to car-
diometabolic dysregulation in separate sections.
Metabolic dysregulation. An independent association
betweenOSA, insulin resistance, and type 2 diabetes has been
consistently demonstrated by a number of cross-sectional
studies, observational studies, and large population-based
studies (22–25). Moreover, the development of insulin
resistance and pancreatic beta cell dysfunction has been linked
to chronic intermittent hypoxemia observed in OSA (26).
Even mild recurrent oxyhemoglobin desaturations (>2%)
were independently associated with metabolic dysfunction
(27). The causal role of intermittent hypoxia in insulin
resistance has been further proven in a mouse model of
OSA. Lean C57BL/6J mice developed insulin resistance
acutely after several hours of hypoxic exposure (28). Chronic
intermittent hypoxia exacerbated fasting hyperglycemia,
glucose intolerance, and insulin resistance in both mice with
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571diet-induced obesity and mice with genetic obesity (29,30).
Thus, animal data suggest that intermittent hypoxia of
OSA and obesitymay interact to causemetabolic dysfunction.
The role of intermittent hypoxia has also been shown in
humans. Healthy volunteers were exposed to 6 h of inter-
mittent hypoxia and developed insulin resistance and
impaired beta cell function (31). Regarding lipid metabolism,
consistent evidence from animal models of OSA has
shown that chronic intermittent hypoxia induces fasting
dyslipidemia in both lean and obese mice due to activation of
the transcription factor sterol regulatory element-binding
protein 1 and an important downstream enzyme of triglyc-
eride and phospholipid biosynthesis, stearoyl-CoA desatur-
ase-1 (32–34). Moreover, chronic intermittent hypoxia
also impaired clearance of triglyceride-rich lipoproteins,
inactivating adipose lipoprotein lipase (35,36). In humans,
a randomized study showed that treatment of OSA with
continuous positive airway pressure (CPAP) improves post-
prandial triglyceride and total cholesterol levels (37). Despite
this evidence, there are no consistent data suggesting that
OSA is a major risk factor for dyslipidemia (38).
In themetabolic syndrome scenario, occultOSA is common
and independently associated with increased serum levels of
triglycerides and glucose as well as with several metabolic and
inﬂammatory parameters not included in the criteria for
metabolic syndrome (cholesterol/high-density lipoprotein
cholesterol ratio, uric acid, and C-reactive protein) (4).
Regarding the pathogenic adipose tissue endocrine re-
sponses, inappropriate secretion of several adipokines that
have anti-inﬂammatory, antiatherogenic, and insulin-
sensitizing properties have been described in OSA (39)
but obesity per se is a potential confounding factor (40).
Therefore, the relative role of OSA in adipokines remains to
be established.
Nonalcoholic fatty liver disease. Nonalcoholic fatty liver
disease (NAFLD) represents a spectrum of progressive
stages of liver disease ranging from simple steatosis to
nonalcoholic steatohepatitis manifested by hepatic inﬂam-
mation, necrosis, and ﬁbrosis. NAFLD is strongly linked to
obesity and independently associated with incident and
prevalent cardiovascular disease (41).
Despite the well-known heterogeneous disease spectrum
of NAFLD, the potential triggers for the progression of
NAFLD are not fully understood. Consistent evidence from
both humans and mice suggests that OSA is a potential
candidate for exacerbation of NAFLD in obesity (42).
Polotsky et al. (43) examined whether OSA and nocturnal
hypoxemia predict the severity of steatohepatitis in severely
obese individuals presenting for bariatric surgery. Taking
advantage of the availability of liver biopsy specimens, the
investigators found that patients with moderate to severe
OSA and severe hypoxemia exhibited more severe hepatic
lobular inﬂammation than patients with mild OSA
(Fig. 2). Severe nocturnal hypoxemia was associated with
ballooning of hepatocytes and pericellular ﬁbrosis in the
liver. Similar ﬁndings were described in patients with OSAby another group of investigators (44). Animal studies
conﬁrmed the role of chronic intermittent hypoxia in the
progression of fatty liver in obesity (29).
Sympathetic activity. Previous evidence showed that vari-
ations in sympathetic tone in obese patients are largely
explained by their OSA status. In 1998, Narkiewicz et al.
(45) reported provocative data on muscle sympathetic nerve
activity in healthy normal-weight subjects and healthy
sedentary obese subjects. Polysomnography revealed that 1
of 25 normal-weight subjects and 9 of 30 obese subjects had
occult OSA. Interestingly, muscle sympathetic nerve activity
was similar in normal-weight subjects and obese subjects
without OSA. Muscle sympathetic nerve activity in obese
subjects with OSA was signiﬁcantly higher than that in
obese subjects without OSA. The investigators concluded
that obesity alone, in the absence of OSA, is not accom-
panied by increased sympathetic activity. The major limi-
tation of this pivotal study was the small sample size and the
lack of a control lean group. Seven years later, Grassi et al.
evaluated muscle sympathetic nerve activity in 86 middle-
aged normotensive subjects classiﬁed according to body
mass index (BMI) and apnea/hypopnea index as lean and
obese subjects with and without OSA (46). Subjects with
and without OSA were matched for age, sex, and blood
pressure values within the lean and obese groups. Compared
with the non-OSA lean group, there were similar increases
in muscle sympathetic nerve activity in the OSA lean and
the non-OSA obese groups, whereas a further increase was
detected in obese patients with OSA (Fig. 3). These results
suggested that sympathetic activation in obesity occurs
independently of OSA but OSA has an additive sym-
pathostimulating effect (46).
Two independent groups of investigators recently ex-
plored whether the sympathetic hyperactivity observed in the
metabolic syndrome is further exacerbated by the presence
of OSA (47,48). Both groups reported that patients with
the metabolic syndrome and comorbid OSA have higher
sympathetic drive and diminished baroreﬂex sensitivity
compared with patients with the metabolic syndrome
without OSA. CPAP therapy reduces muscle sympathetic
nerve activity in patients with OSA (49).
Overall, current evidence implicates OSA in potentiating
sympathetic activity in obese patients. It is conceivable that
the sympathetic activation is induced by hypoxia via
peripheral chemoreceptors (50).
Endothelial dysfunction, surrogate markers of athero-
sclerosis, and arterial stiffness. Several reports consistently
showed that OSA is independently associated with endo-
thelial dysfunction (51,52) and that treatment of OSA
with CPAP signiﬁcantly improved endothelial function
(53,54). However, a systematic analysis of endothelial dys-
function in obese patients with and without OSA was
performed only recently. Jelic et al. (55) measured bra-
chial artery ﬂow-mediated dilation, an indirect marker of
endothelial nitric oxide (NO)-mediated reactivity, in 71
subjects with a BMI ranging from normal to obese who
Figure 2 Nonalcoholic Fatty Liver Disease in Severely Obese Individuals According to the Presence or Absence of OSA
(A) Representative image of the liver without inﬂammation in a subject without OSA. Macrovesicular hepatic steatosis is evident, but inﬂammation is absent (hematoxylin-eosin;
original magniﬁcation 100). (B) Representative image of the liver in a subject with OSA and severe nocturnal oxyhemoglobin desaturation. Macrovesicular hepatic steatosis is
evident, and lobular inﬂammation is present (arrows) (hematoxylin-eosin; original magniﬁcation 100). (C) Representative image of liver without pericellular ﬁbrosis in an
individual without OSA (Masson trichrome; original magniﬁcation 100). (D) Representative image of liver in a subject with OSA and severe nocturnal oxyhemoglobin desa-
turation. Prominent pericellular perisinusoidal ﬁbrosis is present. Collagen depositions are stained blue and have a chicken-wire appearance (Masson trichrome; original
magniﬁcation 100). Reprinted with permission from Polotsky et al. (43). Abbreviation as in Figure 1.
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572underwent polysomnography. Proteins that regulate basal
NO production and inﬂammation and markers of oxidative
stress were quantiﬁed in venous endothelial cells. The
investigators reported that expression of endothelial
NO synthase (eNOS), phosphorylated eNOS, and ﬂow-
mediated dilation were signiﬁcantly lower (Fig. 4),Figure 3 Sympathetic Activity in Lean and Obese Subjects Accordin
Muscle sympathetic nerve activity (MSNA) in lean (L) and obese (O) subjects according t
permission from Grassi et al. (46). Abbreviation as in Figure 1.whereas expression of nitrotyrosine (a marker of oxidative
stress) was signiﬁcantly greater in patients with OSA than
in OSA-free subjects regardless of central adiposity.
Expression of nuclear factor kB, a marker of inﬂammation,
was greater in obese patients with OSA than in obese
OSA-free subjects. Effective treatment of OSA with CPAPg to the Presence or Absence of OSA
o the presence (þ) or absence () of OSA. *p < 0.05; **p < 0.01. Reprinted with
Figure 5
Carotid Intima-Media Thickness in Patients With
Metabolic Syndrome With and Without OSA
Carotid intima-media thickness (IMT) in patients with metabolic syndrome (MS)
according to the presence or absence of OSA. Reprinted with permission from
Drager et al. (58). Abbreviation as in Figure 1.
Figure 4
Endothelial Dysfunction in Normal, Overweight, and
Obese Subjects According to the Presence or
Absence of OSA
Flow-mediated dilation (FMD) in normal (N), overweight (OV), and obese (O) strat-
iﬁed by body mass index (BMI) and as having central obesity by increased (I) vs
normal (N) waist circumference or waist-to-hip ratio. Reprinted with permission
from Jelic et al. (55). Abbreviation as in Figure 1.
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573signiﬁcantly increased ﬂow-mediated dilation and expres-
sion of eNOS and phosphorylated eNOS, whereas expres-
sion of nitrotyrosine and nuclear factor kB signiﬁcantly
decreased (55). More recently, Namtvedt et al. also reported
a positive association between severity of OSA and impaired
endothelial function independently of obesity and other
cardiovascular risk factors (56). In the metabolic syndrome
scenario, Akishita et al. (57) found that patients with both
the metabolic syndrome and OSA had lower ﬂow-mediated
dilation than patients with the metabolic syndrome alone or
controls. Regarding surrogate markers of atherosclerosis and
arterial stiffness, a previous investigation found that patients
with both the metabolic syndrome and OSA had higher
values of carotid intima-media thickness (Fig. 5), pulse wave
velocity, and carotid diameter. The apnea-hypopnea index
was independently associated with impairments in these 3
vascular parameters (58). Finally, in a preliminary single-
arm study, Oyama et al. (59) reported that CPAP therapy
improved endothelial dysfunction and decreased markers of
oxidative stress in patients with the metabolic syndrome and
OSA. Taken together, these ﬁndings suggest that OSA has
an independent effect on endothelial dysfunction, surrogate
markers of atherosclerosis, and arterial stiffness in obesity
and the metabolic syndrome.
High blood pressure. The relationship between OSA and
high blood pressure is supported by a large body of evidence
and has been extensively discussed in previous reviews
(60,61). Increased blood pressure in patients with OSA is
multifactorial in origin and may depend on sympathetic
overactivity, systemic inﬂammation, oxidative stress,
endogenous vasoactive factors, and endothelial dysfunction
(60,61).Regarding the impact of OSA treatment on blood pres-
sure, a previous meta-analysis not involving drug-resistant
hypertension suggested a very modest impact of CPAP on
blood pressure (approximately 2.5 mm Hg for systolic blood
pressure and 2 mm Hg for diastolic blood pressure) (62) but
very heterogeneous populations (including normotensive
patients) were combined, which potentially may mitigate the
effects. The results of recent randomized studies suggest that
the effect of CPAP is more signiﬁcant in the subgroup of
patients with uncontrolled and drug-resistant hypertension
(63,64). More recently, Drager et al. (65) showed that 3
months of CPAP therapy normalized blood pressure in
patients with OSA who had pre-hypertension and masked
hypertension. This result suggests that treatment of OSA
may prevent the development of sustained hypertension.
Despite the aforementioned evidence, there is a paucity of
data that speciﬁcally address high blood pressure in patients
with OSA according to the presence or absence of obesity
and the metabolic syndrome. Previous investigations showed
inconsistent results. For instance, studies of the adrenergic
overdrive in obesity and the metabolic syndrome did not show
further increases in blood pressure in patients with OSA
(46,47). In contrast, Trombetta et al. (48) found that patients
with the metabolic syndrome and OSA had higher blood
pressure than patients with the metabolic syndrome alone.
Further studies with a higher sample size and analysis of 24-h
ambulatory blood pressure monitoring should clarify this issue.
Heart remodeling and arrhythmias. Recent evidence
indicates that OSA is independently associated with incident
heart failure (66). There are multiple mechanisms by which
OSA could lead to heart remodeling, including exacerbation
of nighttime and daytime hypertension, increased sympathe-
tic tone, increased left ventricular afterload due to increa-
sed arterial stiffness, and exaggerated swings in intrathoracic
pressure during obstructive episodes, among others (67–69).
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574The impact of OSA on heart remodeling has recently been
explored in obese patients. Avelar et al. (70) performed
echocardiography and laboratory testing in 455 severely obese
subjects and 59 nonobese reference subjects and showed that
more severe nocturnal hypoxemia, increased systolic blood
pressure, andBMI are independently associatedwith increased
left ventricular mass. Otto et al. compared the cardiac struc-
tural and functional changes in obese and otherwise healthy
adults with and without OSA (71). Obese patients with OSA
had an increased left atrial volume index and altered diastolic
function comparedwith similarly obese patients withoutOSA,
which implicates OSA in early subclinical impairment of
cardiac function (71). Taken together, the early cardiac
changes induced by OSAmay contribute to heart remodeling,
heart failure, and arrhythmias reported in obese patients.
Indeed, in a retrospective cohort study of 3,542 adults in
Olmsted County, Minnesota, obesity and the magnitude of
nocturnal oxygen desaturation were independent risk factors
for incident atrial ﬁbrillation in individuals <65 years of age
(72). It is conceivable that structural changes in the left atrium
may contribute to an increased risk of atrial ﬁbrillation in
patients with OSA (68). Recent detailed electrophysiological
and electroanatomic mapping found an abnormal atrial
substrate in patients with OSA compared to age- and BMI-
matched controls without OSA (73). The patients with
OSA showed both structural changes, including increased
atrial size and extensive areas of low voltage, and regions of
electrical silence and conduction abnormalities (73).
Regarding the impact of treatment of OSA on atrial ﬁbrilla-
tion, appropriate treatment with CPAP in patients with OSA
is associated with lower recurrence of atrial ﬁbrillation at 12
months compared with untreated patients (74).
Reversing metabolic syndrome components in the treatment
of patients with OSA. Recent studies were designed to
explore the impact of OSA on the metabolic syndrome and its
components (75–78). In a nonrandomized study, Dorkova
et al. showed that CPAP therapy reduced several components
of themetabolic syndrome in patients who usedCPAP for4
h/night for 8 weeks, including blood pressure, triglyceride
levels, and glucose levels, compared with patients with low
adherence to CPAP (<4 h/night) (75). More recently,
Sharma et al. performed a crossover, double-blind, random-
ized study exploring the impact of treatment with CPAP for 3
months on components of the metabolic syndrome (76). In
this study, treatment with CPAP (vs. sham CPAP [i.e.,
a placebo]) was associated with signiﬁcant mean decreases in
systolic blood pressure, diastolic blood pressure, serum total
cholesterol levels, low-density lipoprotein cholesterol levels,
triglyceride levels, and glycated hemoglobin. The prevalence
of the metabolic syndrome was signiﬁcantly reduced after
CPAP therapy (reversal found in 11 of 86 patients [13%]
undergoing CPAP therapy vs. 1 of 86 [1%] undergoing sham
CPAP) (76). Surprisingly, treatment withCPAP also reduced
BMI and visceral adiposity, which may partially explain the
metabolic improvement (76). The reduction in BMI and
visceral adiposity after the use of CPAP for the treatment ofpatients with OSA is in contrast to other reports (77,78).
However, an important caveat is that none of the studies
discussed in the preceding text fully controlled for physical
activity and diet pre-intervention and post-intervention.
Further studies are necessary to clarify these important issues.Perspectives
The current literature clearly shows that OSA is an emerging
risk factor for modulating the cardiometabolic consequences
of obesity. There is consistent evidence from animal models
and clinical studies suggesting that OSA augments metabolic,
inﬂammatory, autonomic, vascular, and cardiac dysfunction
of obesity and exacerbates the metabolic syndrome. However,
OSA is commonly underdiagnosed. Several challenges and
research priorities should be mentioned. First, we need to call
attention to the need for more screening for OSA in patients
with obesity and the metabolic syndrome. We should keep in
mind that traditional risk factors for OSA such as excessive
daytime somnolence may not be present in a signiﬁcant
proportion of patients (4). It would be important to actively
pursue other symptoms and clinical characteristics such as
frequent snoring and difﬁcult-to-control hypertension,
nocturnal blood pressure abnormalities, atrial ﬁbrillation, or
left ventricular hypertrophy. Second, there is an urgent need
to provide a cost-effective way to appropriately screen for and
diagnose OSA in millions of patients with obesity and/or the
metabolic syndrome. Portable monitoring (79) and new
technologies for diagnosing OSA (80) are promising options
in high-risk groups, given that full polysomnography may not
be readily available. Third, despite the tight link between
obesity and OSA, it is not clear why a signiﬁcant proportion
of obese patients, including those with severe forms of
obesity, do not develop OSA. Comprehensive genetic studies
with anatomic and functional upper airway assessment should
be undertaken to elucidate protective mechanisms (81).
Fourth, there is a clear reciprocal interaction between obesity
and OSA, but there are several gaps in knowledge (82).
Therefore, there is a clear demand for additional research at
both the basic science and clinical levels to understand the
mechanisms by which OSA and its components exacerbate
metabolic dysfunction and vascular impairment in obesity and
the metabolic syndrome. Finally, large randomized clinical
studies will be necessary to deﬁne the impact of treatment of
OSA on metabolic and cardiovascular outcomes.
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